Breaking down the facts of Ozempic (semaglutide), a type 2 diabetes treatment

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

(BPT) - Novo Nordisk is a healthcare company with a 100­-year history of driving change to improve the lives of people living with serious, chronic diseases. As broader conversations about diabetes medicines are ongoing in both mainstream and social media, we believe it is important to continue to raise awareness and to reinforce our commitment to responsible use of Novo Nordisk medicines. These efforts are intended to support the safety of all people for one of our medicines that is well known in the diabetes community, Ozempic®.

See Medication Guide: bit.ly/OzempicPI & Safety Info: bit.ly/OzempicISI for Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg.

Infographic addressing misinformation regarding Ozempic


Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  253.71
+2.52 (1.00%)
AAPL  336.13
-0.87 (-0.26%)
AMD  559.82
+14.73 (2.70%)
BAC  57.73
-0.45 (-0.77%)
GOOG  344.41
+0.73 (0.21%)
META  665.75
-16.56 (-2.43%)
MSFT  493.78
-3.97 (-0.80%)
NVDA  222.27
+2.93 (1.34%)
ORCL  147.61
-2.98 (-1.98%)
TSLA  364.27
-1.93 (-0.53%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.